A*STAR researchers have identified specific sites in the surface protein of influenza viruses that allow the pathogen to adapt to different host organisms.
Targeted mutagenesis is being used to create live-attenuated vaccines against the chikungunya virus.
A*STAR scientists have found a way to strengthen the immune response to adenovirus infection using engineered antibodies.
new technologies shed light on the origin and maturation process of key immune
A more efficient production process for influenza vaccines could help to cope with future pandemics
Manipulating a population of blood cells in an individual could help to activate immune responses against the hepatitis B virus
A technique for analyzing specific T-cell responses could pave the way for more rationally designed vaccines
A*STAR’s new vaccine, based on a virus-like particle technology created by Cytos Biotechnology AG, could strengthen Singapore’s ability to tackle influenza pandemics
Exploiting the early immune response in Chikungunya fever promises to provide protection
A vaccine against a devastating form of malaria common in Asia and South America is one step closer thanks to a long-awaited methodological advance
Genomic technologies developed by A*STAR’s Singapore Immunology Network (SIgN) form the basis for a new vaccine development platform that could pave the way for cost-effective personalized therapy